Analysts are weighing in today on drug maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and fitness tech firm Fitbit Inc (NYSE:FIT). Here’s a quick roundup of today’s bullish brokerage notes on VRX and FIT.

Valeant Pharmaceuticals Intl Inc

Guggenheim analyst Louise Chen reiterated a Buy rating on shares of Valeant Pharma, with a price target of $195, which represents a potential upside of 104% from where the stock is currently trading. The analyst reflects on Walgreen’s agreement, which only began on 1/15 and available prescription data looks promising.

Chen wrote, “VRX’s agreement with WBA got off to a strong start in its first week, with strong weekly Rx growth for key dermatology products; Jubila (+5%), Solodyn (+17%), Onexton (+24%), and Retin-A Micro (+48%). New Rxs were a key driver of this growth. The strong NRx growth supports our prior diligence where dermatologists expressed their liking of, and continued willingness to use, VRX’s products. In our recently published note we estimate that $1.3B in sales could flow through WBA, which would translate into an incremental $1.35 to EPS by ’20.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Louise Chen has a yearly average return of -1.3% and a 40.3% success rate. Chen has a -30.9% average return when recommending VRX, and is ranked #2467 out of 3622 analysts.

Out of the 17 analysts polled by TipRanks in the last 3 months, 9 rate Valeant stock a Buy, while 8 rate the stock a Hold. With a return potential of 63.76%, the stock’s consensus target price stands at $156.64.

Fitbit Inc

Oppenheimer analyst Andrew Uerkwitz initiated coverage on shares of Fitbit, with an Outperform rating and price target of $25, which implies an upside of 50% from current levels.

Uerkwitz wrote, “Fitbit is a leader in the wearables space as it sells devices and operates a global social fitness network. We see this market as just beginning. We see today’s lifestyle trackers as equivalent to early PDAs: a device that has limited functionality but a precursor to something much larger. The “quantified self” is the next step in the evolution of both fitness and digital health—two markets that we believe are poised for tremendous growth over the next 5-10 years—and to us, Fitbit is best positioned to benefit from both growing markets.”

According to, analyst Andrew Uerkwitz has a yearly average return of 1.9% and a 51.6% success rate. Uerkwitz is ranked #856 out of 3622 analysts.

Out of the 18 analysts polled by TipRanks, 14 rate Fitbit stock a Buy, while 4 rate the stock a Hold. With a return potential of 153%, the stock’s consensus target price stands at $42.25.